Analysis of morphine in plasma by radioimmunoassay is complicated by interference from morphine metabolites, particularly morphine-3-glucuronide. This interference makes radioimmunoassay a poor technique to study the pharmacokinetics of morphine in man. The method described here is one which uses commercially available anti-morphine antiserum and separating reagent with a simply prepared iodinated morphine derivative. Cross-reactivity to morphine metabolites is negligible and the method correlates well with HPLC. Results obtained for pharmacokinetic parameters after intravenous administration in man are in agreement with published data using GLC or HPLC. The method is inexpensive, simple and rapid; choice of a different antiserum could allow the method to be used for screening for drugs of abuse such as morphine, diamorphine, codeine and dihydrocodeine.
Although the sensitivity of radioimmunoassay is greater than liquid chromatography (HPLC) or gas-liquid chromatography, cross-reaction of antisera with metabolites has proved to be a major problem. I. 2 Morphine is extensively metabolised to morphine-3-glucuronide, although nor-morphine and morphine-6glucuronide are also produced in small amounts." Other metabolites are possible but are not considered important in man after parenteral administration.
The measurement of morphine is usually undertaken either for drug disposition studies or to determine the presence of drugs of abuse. In the latter case, cross-reaction to the glucuronide may actually be beneficial, because morphine glucuronide is the major metabolite present in urine. However, anything more than minimal interference is unacceptable for pharmacokinetic studies." Selective organic solvent extraction of morphine from plasma" may give low extraction efficiency and impose additional potential errors.
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This paper describes a simple radioimmunoassay for morphine in plasma. The method uses commercially available antiserum andsolid-phase second antibody together with a simply prepared iodine-labelled morphine. One antiserum yielded negligible crossreactivity to morphine-3-glucuronide, and this assay was used to determine intravenous morphine kinetics in patients undergoing laminectomy.
Methods

REAGENTS
Buffer
Stock buffer consisted of 0·5 mollI NalK phosphate, pH 7·5. This was diluted 1:10 with distilled water to provide working buffer with the addition of 0·5% (v/v) Triton X-lOG (BDH, Poole, Dorset) and 0·1 % (w/v) sodium metabisulphite.
Standards
Morphine sulphate pentahydrate BP (Evans Medical, Greenford, Middlesex) was dissolved in 30% (v/v) methanol to produce a stock Morphine radioimmunoassay with iodine label 319 standard of 264 nmolll (100 ng/ml) which was stored frozen in aliquots for several months. For each assay an aliquot was double-diluted in working assay buffer to provide standard solutions over the range 1-264 nmolli. Morphine concentrations were expressed as nmolll (1 nmol/l = 0·28 nglml morphine base) to avoid the confusion which has arisen when authors have failed-to specify whether concentrations were expressed as base or salt.
Controls
Drug-free human plasma was centrifuged to remove precipitated proteins. Sodium metabisulphite was added to give a final concentration of 0·1% (w/v) , and small volumes of stock standard of morphine sulphate pentahydrate in 30% methanol were added to produce control pools in the range 4-120 nmol/l. The pools were aliquoted in approximately 0·5 ml volumes and stored frozen.
Antisera
The antisera were all commercially available. Goat anti-morphine antiserum was supplied as neat serum (Bioanalysis Ltd, Cardiff), and on arrival it was diluted with a similar volume of drug-free human plasma, mixed, aliquoted and stored at -20°C. Rabbit anti-morphine antiserum (Damon Diagnostics) was a gift from IRE UK Ltd, High Wycombe, and was stored at 4°C. Sheep anti-morphine antiserum (Technam Inc, Park Forest South, Illinois) was a gift from Dr P A Mason of the Home Office Central Research Establishment, Aldermaston. The conjugation schedules for haptenisation were not given for any of these antisera.
Solid-phase second antibody
Donkey anti-sheep/goat or donkey anti-rabbit antisera coupled to cellulose beads (Sac-Cel , Wellcome Diagnostics, Dartford), were diluted 1:1 with working buffer. This reagent was thoroughly stirred and was at room temperature for use.
IODINATION TECHNIQUE
A 1 mglml solution of lodogenf (1,3,4, 6-tetrachloro-3,6-diphenylglycouril, Pierce & Warriner (UK) Ltd, Chester) in dichloromethane was diluted 1:30 with dichloromethane. A 30 Jotl volume was pipetted into a small glass vial and the solvent evaporated under a stream of nitrogen. To the reaction vessel were added 10 Jotl volumes of solutions of stock buffer, 125 1 as NaI (1 mCi, Amersham International, Amersham, Bucks) and approximately 2 Jotg morphine sulphate pentahydrate. The contents were mixed with gentle swirling, and the reaction allowed to continue at room temperature for 11 minutes, with intermittent gentle mixing. At the end of the reaction time, 0·2 ml working buffer was added.
An octadecylsilica Bond-Elute cartridge (Jones Chromatography, Llanbradach, Glamorgan) was primed with 2 ml methanol followed by 4 ml distilled water. The contents of the reaction vial were then transferred to the top of the cartridge, together with four successive reaction-vial washings with 0·2 ml working buffer. This volume of approximately 1 ml was forced through the cartridge under positive pressure (fraction 1). Eight washes each of 2 ml of distilled water were similarly forced through, and collected as separate fractions. Finally five washes of 2 ml methanol were applied and collected as separate fractions.
A small aliquot (10 Jotl) of each fraction was diluted into 1 ml buffer and the radioactivity counted. The methanol fractions with the highest count rates were combined and stored at 4°C. For use in the radioimmunoassay, tracer was diluted in working buffer to produce about 300000 cpm/ml (30000 cpm/assay tube).
ASSAY PROCEDURE
Volumes of standards, samples or controls (typically 20 Jotl) were pipetted into roundbottomed plastic tubes (LP3, Luckhams, Burgess Hill, Sussex) followed by 100 Jotl volumes of both label and antiserum diluted in working buffer. The antiserum dilution was chosen to produce approximately 50% binding of label at zero dose. Tubes were vortexed and incubated at room temperature for 15 minutes. Then 100 Jotl of diluted Sac-Cel was added, the tubes mixed and again incubated at room temperature for 15 minutes. Finally 2 ml of distilled water was added and the tubes centrifuged at 2000 g for 5 minutes. Supernatant fluid was aspirated and the white precipitate counted for 1 minute on a multihead gamma counter (Multigamma, LKB Ltd, Selsdon, Surrey). Percentage binding [100 (B -NSB)/ (B II -NSB)] of standard samples was calculated and fitted to a spline function; results of unknown samples were calculated automatically. The cross-reactivity of the three antisera was tested at antiserum concentrations giving approximately 50'¥0 binding at zero dose; the assay conditions included working buffer and the presence of human heparanised plasma. The molar cross-reactivities to morphine-3glucuronide, nor-morphine, codeine, dihydrocodeine and diacetylmorphine, as well as some other narcotics, are given in Table 1 . u fraction is shown in Figure 1 . A small amount of radioactivity was recovered in the early fractions, where NaI has been shown to elute in this system. The greater part of the radioactivity was collected in fraction 10, the first methanol wash. Fractions 10 and 11 were combined to form the stock label, with a count rate of about 2 x 10 8 cpm/ml; this represented a minimum specific activity of 100 /-LCi//-Lg morphine sulphate. The iodinated morphine proved to be stable; no chromatographic breakdown was seen after 5 months storage at 4°C, and it could be used for at least 4 months without any noticeable deterioration in the radioimmunoassay.
CORRELATION WITH HPLC
Samples of plasma obtained from patients at various times after intravenous morphine ad-
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Results
PHARMACOKINETIC STUDY
Ethical committee approval was obtained to study patients undergoing elective laminectomy at the Radcliffe Infirmary, Oxford. Patients were selected if they were aged less than 60 years and weighed between 40 and 100 kg. Those with severe cardiac, hepatic, renal or metabolic disease were excluded; no patient had a history of regular narcotic medication.
Patients were premedicated with intramuscular pethidine (1 mg/kg to the nearest 25 mg) and atropine (0,6 mg) 2 hours before operation. Anaesthesia was induced with sodium thiopentone 4 mglkg; patients were intubated and anaesthesia maintained with 33% oxygen in nitrous oxide, with halothane (0'5%) supplementation as required. Muscular relaxation was with pancuronium bromide 0·1 mg/kg intravenously.
Before the start of surgery patients were given intravenous morphine sulphate pentahydrate (morphine sulphate injection B.P., Evans Medical, Greenford, Middlesex); 10 mg was diluted in 10 ml saline and injected into a flowing infusion over a period of 20 seconds. All sample times were taken from the end of the injection. Blood samples were collected for morphine estimation from a central venous cannula at 1, 2, 3, 5, 7,5, 10, 15,20,30,60,90, 120 and 180 minutes. Samples were collected into tubes containing lithium heparin anticoagulant and stored cold until centrifuged; after centrifugation plasma was frozen until analysis.
Plasma morphine concentrations from individual patients were fitted to a sum of exponentials curve using a non-linear least-squares program." The data was run as biexponential fits and weighting was not used. Kinetic parameters were then calculated from the fitted data." ministration were analysed both by radioimmunoassay and by an HPLC method which has been shown to be specific for morphine." About half of these samples were obtained from patients in renal failure undergoing kidney transplant operations, and the remainder from patients undergoing cardiopulmonary bypass surgery. Zero-dose tubes were incubated for various times before addition of 100 ILl of working Sac-Cel, after which incubation continued at room temperature for 15 minutes. The equilibrium was attained by 5 minutes incubation under these conditions (Fig. 2b) for all three anti-morphine antisera. Similarly, the time required to attain equilibrium between antimorphine antiserum and Sac-Cel at room temperature was about 5 minutes ( Fig. 2c) for all three anti-morphine antisera. The working range of the assay was established by using volumes of standards between 10 and ioo ILl (Fig. 3 ). Use of 100 ILl yielded great sensitivity down to about 1 nrnol/l, but for ; 30 u T Antisera from both Damon and Technam had significant (9'Yo) cross-reactivity .to morphine-3-g1ucuronide. in contrast to that from Bioanalysis, which also had the lowest cross-reactivity to codeine. None of the antisera had significant cross-reactivity to normorphine. Cross-reactivity to codeine. dihydrocodeine and diacetylmorphine varied greatly between the antisera. No narcotic unrelated to morphine could be shown to displace binding from any of the antisera. and cross-reactivity to compounds with the basic morphinan structure like naloxone and naltrexone was also negligible.
Cross-reactivity relative to morphine was determined at antiserum concentrations which gave S()% tracer binding at zero dose in the presence of human plasma.
ASSAY VALIDATION
The volume of Sac-Cel required to precipitate the anti-morphine antiserum completely was investigated by the addition of different volumes of undiluted Sac-Cel to zero dose and non-specific binding tubes. Incubations were at room temperature. and for 15 minutes for the first incubation between label and antimorphine antiserum and that with Sac-Cel, The results ( Fig. 2a ) demonstrated that maximum binding was obtained with 50 ILl undiluted Sac-Cel with all three anti-morphine antisera. Non-specific binding was always less than 3% of total radioactivity. For routine use Sac-Cel was diluted 1: I with working buffer. and a llJO ILl volume was used.
The time required to attain equilibrium between anti-morphine antiserum and morphine label at room temperature was assessed. 
A. Standard displacement curve
Mean ± SEM (n = 6) given 10 mg morphine sulphate intravenously are shown in Fig: 4 ; the range of concentrations obtained up to 3 hours after the dose was in excess of 50 nmoili. Pharmacokinetic analysis
Data for standard displacement curves was obtained from six routine assays. Interassay precision was assessed using three pools with morphine added to drug-free human plasma, each of which was measured in 25 separate assays. Forty-eight plasma samples were measured by radioimmunoassay using Bioanalysis antiserum and by HPLC with extraction, ion-paired reverse-phase chromatography and electrochemical detection. The results were not significantly different; linear least-squares regression of radioimmunoassay against HPLC produced a slope which was close to unity (0,95 ± 0·03, mean ± SEM) and an intercept which was not significantly different from zero. The correlation coefficient was 0·97 (P<O·OOl).
B. Interassay precision
INTRAVENOUS MORPHINE KINETICS
Plasma morphine concentrations in 14 patients
routine use a 20 ILl sample volume produced a standard range which was most useful. Recovery of morphine added to plasma ranged between 87 and 104% (95·4 ± 4,9, mean ± SD, n = 9).
No significant effect of differing amounts of human plasma on the displacement of morphine standards could be demonstrated when up to 100 ILl was added to the assay. Human plasma samples with high morphine concentrations were serially diluted with working buffer. These produced curves which were parallel with the standard curve (not shown), but omission of Triton X-100 from the working buffer yielded curves which were not parallel.
The displacement produced by standard morphine solutions was consistent ( Table 2) . Between-batch coefficients of variation for morphine control samples were less than 10% at concentrations between 4 and 114 nrnol/l in routine use.
Minutes
5000
Discussion
Half-life was calculated as T 1 / 2 = logc2lrate constant. methods using electrochemical detectors?' 12 which have a similar sensitivity.
Radioimmunoassay has the implied advantage of higher throughput combined with great sensitivity, but the complex inter-relationships of morphine and its metabolites meant that few antisera had sufficiently low cross-reactivity for use in pharmacokinetic experiments. I. 2, 13 The use of extraction to avoid interference by morphine glucuronides'' substantially increases the difficulty of the assay and imposes additional potential errors because of incomplete recovery.
The method described here had low crossreaction with morphine metabolites when the antiserum obtained from Bioanalysis was used. The conjugation schedule for this antiserum was not given, though the low cross-reactivity to both morphine-3-glucuronide and normorphine suggests conjugation through position 6. 13 Interference from morphine-6glucuronide might be possible; this is generally considered to be a minor metabolite;' though recent work!" suggests that it may be present in patients taking high-dose oral morphine (600 mg daily). In any event, this radioimmunoassay gave excellent correlation with an HPLC method specific for morphine. The assay using Bioanalysis antiserum would therefore be useful for pharmacokinetic purposes, though not in situations where heroin was also given.
For toxicological use, where detection of glucuronides may be desired, the antisera which displayed significant cross-reactivity to morphine-3-glucuronide would be preferable. The Bioanalysis antiserum might possibly be useful for the detection of heroin or monoacetylmorphine under special circumstances where care had been taken to minimise hydrolysis of these to morphine. 3 The high cross-reaction with codeine obtained with antisera from Technam and Damon suggested that these antisera were raised by haptenisation through position 3, as neither cross-reacted significantly with nor-morphine.
The product of morphine iodination was not identified, but, using chloramine T as oxidising agent, it has been identified by mass spectrometry as 2-iodomorphine. 15 The present iodination technique gives more control over iodination than does the use of chloramine T. In addition, solid-phase adsorption of the iodinated product on to octadecylsilica columns, and subsequent elution with methanol is much faster than previously used gel filtration, In and safer than organic solvent extraction. Morphine has been measured in the past by a variety of methods. Oxidation of morphine to pseudomorphine and its subsequent measurement by fluorescence was insensitive,') though coupling to HPLC allowed concentrations of above 50 nmol/l to be measured. III A sensitive (3 nmol/l) and specific gas-liquid chromatographic analysis for morphine has been described, 1 I but is technically demanding and has low throughput. This is also true for HPLC ( Although the separation technique removed unreacted iodine, it is not known whether uniodinated morphine was also removed. Previous work" suggests that it was not, though this in no way affected the sensitivity of the assay over the desired concentration range. The method could be used to detect as little as 1 nmol/l of morphine using 100 J-Ll of plasma. This represents 100 fmol/assay tube, and is sufficiently sensitive for morphine assays in man under most clinical circumstances. It has, for instance, been used to measure the low plasma concentrations found after intradural injections of a few milligrams of morphine.!" No apparent matrix effect was observed when different amounts of heparinised plasma were added to the assay system, and dilution of samples of high morphine concentration with assay buffer yielded curves parallel to standards. However, the addition of Triton X-100 to the buffer was found to be essential. Morphine bound avidly to plastic tubes, and omission of the surfactant led to bizarre and unreproducible results. These commonly took the form of high apparent plasma morphine concentrations, presumably due to loss of morphine in the standards. Use of surfactant, as well as sodium metabisulphite to minimise self-oxidation to pseudomorphine overcame these problems and gave reproducible standard curves and acceptable interassay precision assessed by stored plasma pools ( Table 2) .
Application of the standard procedure to the investigation of morphine pharmacokinetics after intravenous injection yielded results for terminal half-life and plasma clearance in good agreement with data in the literature for anaesthetised patients.?: 18. 19 The radioimmunoassay for morphine described here was rapid, inexpensive and used commercially available reagents. Appropriate choice of antiserum could provide an assay with sufficiently low cross-reaction with metabolites for the determination of morphine for pharrnacokinetic analysis.i" Alternatively an antiserum with greater cross-reactivity could be used for screening for abuse of morphine, heroin, codeine or dihydrocodeine.
